Do you advocate for dose dense AC instead of every 3 week dosing in neoadjuvant TNBC as done in KEYNOTE 522?

When giving neoadjuvant therapy for TNBC as given in the KEYNOTE-522 study, I prefer to administer dose dense AC (with growth factor support) + pembrolizumab (after completing weekly paclitaxel and carboplatin + pembrolizumab). While there has been no comparison of dose dense vs. q3week AC with this...

We utilize the regimen scheduled studied in KEYNOTE-522 with q3 week AC. Having given carbo/taxol-ddAC prior to the use of pembrolizumab, I find that the tolerance of AC chemotherapy and count recovery has been better with q3week schedule. Although prior studies have shown improvement of outcomes wi...